Well-differentiated liposarcoma
MONDO:0005103A locally aggressive malignant neoplasm composed of mature adipocytes showing cell size variation and nuclear atypia. It is often associated with the presence of hyperchromatic multinucleated stromal cells, and varying numbers of lipoblasts. There are three histologic subtypes, sclerosing, inflammatory, and spindle cell liposarcoma. These tumors do not usually metastasize unless they undergo dedifferentiation.
Also known as: atypical lipomatous tumor, atypical lipomatous tumour, ALT, WDLS, atypical lipoma, well differentiated liposarcoma, well differentiated liposarcoma of deep soft tissue, well-differentiated liposarcoma
2819 clinical trials for this condition and its sub-types, 5 tagged with Well-differentiated liposarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Well-differentiated liposarcoma
-
Inflammatory liposarcoma 0 trials
-
Sclerosing liposarcoma 0 trials
-
Spindle cell liposarcoma 0 trials
-
New drug duo aims to halt rare cancer's growth
Disease control Recruiting nowThis study tests whether combining two drugs, mirdametinib and palbociclib, can safely slow or stop advanced liposarcoma (a rare soft-tissue cancer). About 54 adults with liposarcoma that has spread or cannot be removed will receive different doses to find the best one. The main …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug duo aims to halt advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SPH4336, given alone or with another drug (cadonilimab), in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the treatment can slow or stop cancer growth. About 63 participants will take part i…
Phase 1/2 • Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC